What's in Neumora Therapeutics, Inc.'s pipeline?

Neumora Therapeutics, Inc. has 2 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 1 in Phase 1.

Which companies overlap with Neumora Therapeutics, Inc.'s portfolio?

Top competitors by shared drug class: Dr. Reddy's Laboratories Limited, Eli Lilly and Company, Otsuka Pharmaceutical Development & Commercialization, Inc..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/neumora-therapeutics-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Neumora Therapeutics, Inc. — Portfolio Competitive Intelligence Brief

Neumora Therapeutics, Inc. pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
NMRA-335140	NMRA-335140	phase 3	5-HT7 receptor antagonist	5-HT7 receptor	Psychiatry/Neurology

Therapeutic area mix

Psychiatry/Neurology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Dr. Reddy's Laboratories Limited · 1 shared drug class
Eli Lilly and Company · 1 shared drug class
Otsuka Pharmaceutical Development & Commercialization, Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Neumora Therapeutics, Inc.:

Cite this brief

Drug Landscape (2026). Neumora Therapeutics, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/neumora-therapeutics-inc. Accessed 2026-05-16.